Marriott International Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Marriott International Inc trades at $363.77 (market cap $94.16B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.41 (market cap $2.27B). The key difference: Marriott International Inc is far larger — about 41.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Marriott International Inc pays a 0.81% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| MAR | SLS | |
|---|---|---|
Market Cap | $94.16B | $2.27B |
Volume | 996,176 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $15.46 |
52-Week Low | $259.04 | $1.39 |
Typical Hold Time | 164 Days | — |
Enterprise Value | $111.47B | $2.14B |
Dividend Yield | 0.81% | — |
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $356.5, down 1.32% on the day, with a bullish technical signal supported by moving averages. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%. Recent earnings beat expectations in Q1 and Q2 2026, while Q3 results are pending. The company maintains strong cash flow from operations at $3.21B and announced a dividend of $0.73 per share payable in September 2026.
The outlook is positive with a consensus price target of $386.71, implying upside. Risks include high debt levels and competitive pressures. Analyst sentiment is mixed with 44% buy ratings, but institutional interest remains strong, supporting a cautiously optimistic view for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →